SALUDA MEDICAL INC (SLD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SLD

SLD - SALUDA MEDICAL INC

FNArena Sector : NONE
Year End: June
GICS Industry Group : Classification Pending
Debt/EBITDA: -1.74
Index: ALL-ORDS

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.42

30 Jul
2026

-0.010

OPEN

$0.43

-2.33%

HIGH

$0.44

847,777

LOW

$0.40

TARGET
$2.27 440.5% upside
FNARENA'S MARKET CONSENSUS FORECASTS
SLD: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 91.5 - 50.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 20242025
EPS Basic xxx-91.5
DPS All xxx0.0
Sales/Revenue xxx108.6 M
Book Value Per Share xxx-297.4
Net Operating Cash Flow xxx-182.6 M
Net Profit Margin xxx-212.21 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20242025
Return on Capital Employed xxx-
Return on Invested Capital xxx-446.03 %
Return on Assets xxx-119.14 %
Return on Equity xxx-
Return on Total Capital xxx-119.75 %
Free Cash Flow ex dividends xxx-184.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20242025
Short-Term Debt xxx200 M
Long Term Debt xxx113 M
Total Debt xxx313 M
Goodwill - Gross xxx-
Cash & Equivalents - Generic xxx83 M
Price To Book Value xxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20242025
Capex xxx2.0 M
Capex % of Sales xxx1.81 %
Cost of Goods Sold xxx58 M
Selling, General & Admin. Exp & Other xxx233 M
Research & Development xxx55 M
Investments - Total xxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

01/07/2026

1

Speculative Buy

$2.94

600.00%

The US FDA has approved the CAP24 surgical paddle lead, allowing Saluda Medical to embark on US commercialisation.

Morgans considers this a key milestone and strategically important as it expands the addressable market whilst enhancing the productivity potential of the commercial platform.

The broker believes that by allowing the existing sales force to address a broader range of procedures with existing hospitals and physicians, the company should be able to materially improve revenue generation per representative, which addresses a key investor concern.

The stock offers high-growth and an execution-led opportunity, Morgans asserts, retaining a Speculative Buy rating and $2.94 target.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -99.58 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -64.43 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

SLD STOCK CHART

FNArena News on SLD

1
FNArena Corporate Results Monitor – 27-02-2026

Feb 27 2026 - Australia
2
Next Week At A Glance – 22-24 Dec 2025

Dec 19 2025 - Weekly Reports